NODAGA-LM3

NODAGA-LM3 is a radiopharmaceutical precursor and diagnostic agent consisting of the chelator NODAGA (1,4,7-triazacyclononane-1-glutaric acid-4,7-diacetic acid) conjugated to the somatostatin receptor (SSTR) antagonist peptide LM3 (p-Cl-Phe-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)-D-Tyr-NH2). It is designed to target cells overexpressing somatostatin receptors, particularly somatostatin receptor type 2 (SSTR2), which are prevalent in neuroendocrine tumors (NETs). As an antagonist, LM3 binds to a broader range of receptor conformations compared to traditional SSTR agonists, potentially leading to higher tumor uptake and improved imaging sensitivity. When radiolabeled with isotopes such as Gallium-68 (68Ga), it is utilized for positron emission tomography (PET) imaging. Chongqing Sintaho provides this molecule as part of its portfolio of linkers and reagents for the development of targeted radiopharmaceuticals and conjugates.

Other names

NODAGA-somatostatin receptor antagonist LM3